



(51) International Patent Classification:

C12N 15/113 (2010.01) *A61K 31/7125* (2006.01)
A61K 31/7088 (2006.01) *C07H 21/02* (2006.01)
A61P 25/02 (2006.01) *C07H 21/04* (2006.01)

(21) International Application Number:

PCT/US2022/080012

(22) International Filing Date:

17 November 2022 (17.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/280,773 18 November 2021 (18.11.2021) US

(71) Applicant: **DTX PHARMA, INC.** [US/US]; 10655 Sorrento Valley Road, Suite 100, San Diego, CA 92121 (US).

(72) Inventors: **SUCKOW, Arthur T.**; c/o DTx Pharma, Inc., 10655 Sorrento Valley Road, Suite 100, San Diego, CA 92121 (US). **ALLERSON, Charles**; c/o DTx Pharma, Inc., 10655 Sorrento Valley Road, Suite 100, San Diego, CA 92121 (US).


(74) Agent: **LEE, Doris** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE

FIG. 6



(57) Abstract: Provided herein are compounds for inhibiting peripheral myelin protein 22 (PMP22) mRNA. Also provided herein are methods of using such compounds for the treatment of Charcot-Marie-Tooth disease.

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*